Mural Oncology (NASDAQ:MURA) Trading Up 8.8% – Should You Buy?

Mural Oncology plc (NASDAQ:MURA) shares rose 8.8% on Thursday . The company traded as high as $4.44 and last traded at $4.43. Approximately 287,501 shares were traded during trading, an increase of 41% from the average daily volume of 204,238 shares. The stock had previously closed at $4.07.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Mural Oncology in a report on Monday, November 11th.

Mural Oncology Trading Up 0.9 %

The firm has a 50-day moving average of $3.68 and a 200 day moving average of $3.49. The company has a market cap of $76.08 million, a P/E ratio of -0.49 and a beta of 3.90.

Hedge Funds Weigh In On Mural Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in MURA. Point72 Asset Management L.P. bought a new position in shares of Mural Oncology during the third quarter valued at about $340,000. Raymond James Financial Inc. purchased a new stake in Mural Oncology in the fourth quarter valued at approximately $181,000. Cubist Systematic Strategies LLC purchased a new position in shares of Mural Oncology during the 2nd quarter valued at about $98,000. Dimensional Fund Advisors LP purchased a new position in shares of Mural Oncology in the second quarter worth about $71,000. Finally, Commerce Bank purchased a new position in shares of Mural Oncology in the third quarter worth $39,000. Institutional investors own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.